Patents Examined by Traviss C. McIntosh, III
  • Patent number: 11660307
    Abstract: Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Anuoluwapo Osinusi, Danielle L. Porter
  • Patent number: 11655268
    Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 23, 2023
    Assignee: ST PHARM CO., LTD.
    Inventors: Kyungjin Kim, Meehyein Kim, Uk-Il Kim, Yun Young Go, Hwajung Nam, Hyung Tae Bang, Jin Soo Shin, Jihye Yoon, Yejin Jang
  • Patent number: 11649261
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: May 16, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • Patent number: 11643431
    Abstract: Disclosed herein is the use of a hyaluronan conjugate for treating pulmonary inflammation, including acute and chronic pulmonary inflammation. Also disclosed herein is the use of a hyaluronan conjugate for treating virus infection. The hyaluronan conjugate is a hyaluronic acid (HA)-nimesulide conjugate.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: AIHOL CORPORATION
    Inventor: Hua-Yang Lin
  • Patent number: 11643428
    Abstract: The present invention relates to a novel therapeutic drug for a neurodegenerative disease and an application thereof. Provided is a novel compound of formula (I). The compound can effectively facilitate the proliferation of neural stem cells in both in vitro and in vivo experiments and can be used as a treatment approach for facilitating neuroregeneration to fight against cognitive decline associated with aging or a neurodegenerative disease.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 9, 2023
    Assignee: Shanghai Pharmaceuticals Holding Co., Ltd.
    Inventors: Gang Pei, Biao Yu, Shichao Huang, Xin Cao, Fuchun Shi, Yue Zhou, Yuqian An, Jing Lu
  • Patent number: 11643660
    Abstract: The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1). In the chemical formula (1), Su is an atomic group having a sugar skeleton at a nucleoside residue or an atomic group having a sugar phosphate skeleton at a nucleotide residue, and may or may not have a protecting group, L1 and L2 are each independently a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms, X1 is an imino group (—NR1—), an ether group (—O—), or a thioether group (—S—), and R1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: May 9, 2023
    Assignees: NEC SOLUTION INNOVATORS, LTD., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Hirotaka Minagawa, Katsunori Horii, Jou Akitomi, Naoto Kaneko, Iwao Waga, Masayasu Kuwahara
  • Patent number: 11638716
    Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 2, 2023
    Assignee: F-star Therapeutics, Inc.
    Inventors: Radhakrishnan P. Iyer, Anjaneyulu Sheri, Geeta Meher, Sreerupa Challa, Shenghua Zhou
  • Patent number: 11634450
    Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of the target protein DOT1L in a subject.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 25, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Scott Armstrong, Paul M. Park
  • Patent number: 11633420
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: April 25, 2023
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • Patent number: 11629165
    Abstract: Molecule having the structural formula (I): (I) for use as targeting probe of translating ribosomes and ribosome-interacting proteins.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: April 18, 2023
    Assignee: IMMAGINA BIOTECHNOLOGY S.R.L.
    Inventors: Massimiliano Clamer, Luca Minati
  • Patent number: 11629164
    Abstract: This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 18, 2023
    Assignee: NuCana plc
    Inventors: Hugh Griffith, Christopher McGuigan, Magdalena Slusarczyk, Michaela Serpi, Valentina Ferrari
  • Patent number: 11618765
    Abstract: The disclosure relates to broad spectrum, direct acting antiviral agents. Disclosed is a group of novel nucleoside and nucleotide analogs having a 4-substituted imidazol-2-one heterocycle in place of the pyrimidine base of natural nucleic acid components and their prodrug derivatives (see Formula I).
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: April 4, 2023
    Inventor: Thomas I. Kalman
  • Patent number: 11613554
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 28, 2023
    Assignees: Bristol-Myers Squibb Company, The Scripps Research Institute
    Inventors: Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
  • Patent number: 11613551
    Abstract: Novel aminoglycosides, represented by Formulae Ia and Ib, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 28, 2023
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventors: Timor Baasov, Shmuel Tuvia
  • Patent number: 11613552
    Abstract: The present disclosure provides compounds of formulas (1)-(3), and compositions and methods of use thereof. The present disclosure also provides methods of preparing a provided compound and composition, and methods of characterizing a provided compound and composition.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 28, 2023
    Assignee: Alltech, Inc.
    Inventors: Zi-Jian Lan, Ronan Power, Alexandros Yiannikouris, Thirupathi Reddy Yerramreddy
  • Patent number: 11608353
    Abstract: There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of ?-amylase.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 21, 2023
    Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Stephen G. Withers, Gary D. Brayer, Leslie Karen Williams, Xiaohua Zhang
  • Patent number: 11603416
    Abstract: The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target ?-glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [?3)-?-D-Manp-(1?4)-?-D-Rhap-(1?]5-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: March 14, 2023
    Assignee: Jiangnan University
    Inventors: Jian Yin, Jing Hu, Juntao Cai
  • Patent number: 11597746
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 7, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J. F. Thuring
  • Patent number: 11597926
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 7, 2023
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Joerg Duschmalé, Martina Brigitte Duschmalé, Henrik Frydenlund Hansen, Troels Koch, Meiling Li, Adrian Schaeublin, Xi Shu, Yong Wu
  • Patent number: 11597741
    Abstract: A process and materials method for making a glucose tetraester may include reacting glucose with a carboxylic acid to create a glucose pentaester. The glucose pentaester was reacted with a basic reagent to create a glucose tetraester. Glucose was reacted with a carboxylic acid anhydride in the presence of 4-dimethylaminopyridine to create a glucose pentaester product. The glucose pentaester reaction product was separated. The glucose pentaester reaction product was reacted with a basic reagent, wherein the reaction steps may take place at a temperature of about 0° C. to about 60° C. and about ambient pressure, wherein the ratio of the carboxylic acid to the glucose was from about 5:1 to about 50:1, and wherein the ratio of the glucose pentaester to the basic reagent was from about 1:50 to about 1:150.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 7, 2023
    Assignee: Myst Labs Inc.
    Inventor: Chenyue Xing